| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:39 UTC |
|---|
| HMDB ID | HMDB0014537 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Nimodipine |
|---|
| Description | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm. |
|---|
| Structure | COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester | ChEBI | | BAY e 9736 | ChEBI | | Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate | ChEBI | | Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate | ChEBI | | Nimodipino | ChEBI | | Nimodipinum | ChEBI | | Nimotop | ChEBI | | Periplum | ChEBI | | Nymalize | Kegg | | 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-b-methoxyethyl ester 5-isopropyl ester | Generator | | 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-beta-methoxyethyl ester 5-isopropyl ester | Generator | | 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 3-β-methoxyethyl ester 5-isopropyl ester | Generator | | 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-b-methoxyethyl ester 5-isopropyl ester | Generator | | 2,6-Dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-methoxyethyl ester 5-isopropyl ester | Generator | | Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid | Generator | | Isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylic acid | Generator | | Andromaco brand OF nimodipine | HMDB | | Bayvit, nimodipino | HMDB | | Cantabria brand OF nimodipine | HMDB | | Hexal, nimodipin | HMDB | | Alpharma brand OF nimodipine | HMDB | | Bayvit brand OF nimodipine | HMDB | | Kenesil | HMDB | | Admon | HMDB | | Brainal | HMDB | | Modus | HMDB | | Nimodipin hexal | HMDB | | Nimodipin-isis | HMDB | | NimodipinISIS | HMDB | | Nimodipino bayvit | HMDB | | Vita brand OF nimodipine | HMDB | | e 9736, Bay | HMDB | | 9736, Bay e | HMDB | | Almirall brand OF nimodipine | HMDB | | Bayer brand OF nimodipine | HMDB | | Calnit | HMDB | | Elan brand OF nimodipine | HMDB | | Esteve brand OF nimodipine | HMDB | | Hexal brand OF nimodipine | HMDB | | Nimodipin isis | HMDB | | Remontal | HMDB |
|
|---|
| Chemical Formula | C21H26N2O7 |
|---|
| Average Molecular Weight | 418.4403 |
|---|
| Monoisotopic Molecular Weight | 418.174001196 |
|---|
| IUPAC Name | 3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
|---|
| Traditional Name | nimodipine |
|---|
| CAS Registry Number | 66085-59-4 |
|---|
| SMILES | COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C |
|---|
| InChI Identifier | InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3 |
|---|
| InChI Key | UIAGMCDKSXEBJQ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. Dihydropyridinecarboxylic acids and derivatives are compounds containing a dihydropyridine moiety bearing a carboxylic acid group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Pyridines and derivatives |
|---|
| Sub Class | Hydropyridines |
|---|
| Direct Parent | Dihydropyridinecarboxylic acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Dihydropyridinecarboxylic acid derivative
- Nitrobenzene
- Nitroaromatic compound
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Benzenoid
- Vinylogous amide
- Enoate ester
- Alpha,beta-unsaturated carboxylic ester
- Amino acid or derivatives
- Carboxylic acid ester
- C-nitro compound
- Organic nitro compound
- Carboxylic acid derivative
- Dialkyl ether
- Secondary aliphatic amine
- Enamine
- Ether
- Azacycle
- Organic 1,3-dipolar compound
- Organic oxoazanium
- Secondary amine
- Propargyl-type 1,3-dipolar organic compound
- Allyl-type 1,3-dipolar organic compound
- Organic oxygen compound
- Carbonyl group
- Amine
- Organopnictogen compound
- Organic nitrogen compound
- Organonitrogen compound
- Organooxygen compound
- Organic zwitterion
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 125 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.012 g/L | Not Available | | LogP | 2.7 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 197.8 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 7.81 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 16.5761 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.77 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 28.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2851.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 326.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 182.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 163.1 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 75.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 492.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 772.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 86.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1306.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 634.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1760.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 475.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 444.4 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 316.8 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 236.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 27.5 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Nimodipine,1TMS,isomer #1 | COCCOC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1 | 2975.2 | Semi standard non polar | 33892256 | | Nimodipine,1TMS,isomer #1 | COCCOC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1 | 2578.8 | Standard non polar | 33892256 | | Nimodipine,1TMS,isomer #1 | COCCOC(=O)C1=C(C)N([Si](C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1 | 3831.3 | Standard polar | 33892256 | | Nimodipine,1TBDMS,isomer #1 | COCCOC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1 | 3195.5 | Semi standard non polar | 33892256 | | Nimodipine,1TBDMS,isomer #1 | COCCOC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1 | 2814.0 | Standard non polar | 33892256 | | Nimodipine,1TBDMS,isomer #1 | COCCOC(=O)C1=C(C)N([Si](C)(C)C(C)(C)C)C(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+](=O)[O-])=C1 | 3838.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Nimodipine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0f6y-8009000000-df297acbb119ead19ae2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Nimodipine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Nimodipine , positive-QTOF | splash10-0006-0149000000-2a019013c0386ca13362 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nimodipine 35V, Positive-QTOF | splash10-0zfu-0039000000-4fc95af4f67b0afb5234 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Nimodipine 35V, Negative-QTOF | splash10-01bc-1654900000-b2486a1feba93aef89fa | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 10V, Positive-QTOF | splash10-014i-5000900000-12c2938a62c8cb238e76 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 20V, Positive-QTOF | splash10-0aor-9002600000-b69caecacf04408cf15b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 40V, Positive-QTOF | splash10-0bt9-9000000000-58c041d65b909517cc19 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 10V, Negative-QTOF | splash10-014i-3000900000-d333c69b2de3907d9af1 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 20V, Negative-QTOF | splash10-0aor-9000600000-d1954bdf68414fdaddb4 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 40V, Negative-QTOF | splash10-0a4i-9000000000-3a47cedd9c89d41d9be5 | 2016-08-04 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 10V, Negative-QTOF | splash10-014i-0004900000-aedc1fdb52380276f236 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 20V, Negative-QTOF | splash10-066r-6049500000-b4e1452bef00eb5c76e4 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 40V, Negative-QTOF | splash10-0002-9020000000-24deee9cc6a1174c9f27 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 10V, Positive-QTOF | splash10-014l-0009400000-10fb7090b7ccce0b345e | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 20V, Positive-QTOF | splash10-0ap3-0079100000-d496424ed4e3b7807f28 | 2021-09-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Nimodipine 40V, Positive-QTOF | splash10-0kdi-0098000000-cae1334e08a3166f17ba | 2021-09-23 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR: Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983 Mar 17;308(11):619-24. [PubMed:6338383 ]
- Belfort MA, Anthony J, Saade GR, Allen JC Jr: A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med. 2003 Jan 23;348(4):304-11. [PubMed:12540643 ]
- Janjua N, Mayer SA: Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care. 2003 Apr;9(2):113-9. [PubMed:12657973 ]
- Vergouwen MD, Vermeulen M, Roos YB: Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review. Lancet Neurol. 2006 Dec;5(12):1029-32. [PubMed:17110283 ]
- Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F: Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens. 2008 Nov;30(8):744-66. doi: 10.1080/10641960802580232. [PubMed:19021025 ]
|
|---|